scholarly journals Beta-Glucans from Fungi: Biological and Health-Promoting Potential in the COVID-19 Pandemic Era

Nutrients ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 3960
Author(s):  
Iwona Mirończuk-Chodakowska ◽  
Karolina Kujawowicz ◽  
Anna Maria Witkowska
Keyword(s):  
Triple Helix ◽  
Biological Response ◽  
Biological Response Modifier ◽  
Key Factors ◽  
Response Modifier ◽  
Factors Influencing ◽  
Beta Glucans ◽  
Health Promoting ◽  
Immunomodulatory Properties ◽  
Helix Conformation

Beta-glucans comprise a group of polysaccharides of natural origin found in bacteria, algae, and plants, e.g., cereal seeds, as well as microfungi and macrofungi (mushrooms), which are characterized by diverse structures and functions. They are known for their metabolic and immunomodulatory properties, including anticancer, antibacterial, and antiviral. Recent reports suggest a potential of beta-glucans in the prevention and treatment of COVID-19. In contrast to β-glucans from other sources, β-glucans from mushrooms are characterized by β-1,3-glucans with short β-1,6-side chains. This structure is recognized by receptors located on the surface of immune cells; thus, mushroom β-glucans have specific immunomodulatory properties and gained BRM (biological response modifier) status. Moreover, mushroom beta-glucans also owe their properties to the formation of triple helix conformation, which is one of the key factors influencing the bioactivity of mushroom beta-glucans. This review summarizes the latest findings on biological and health-promoting potential of mushroom beta-glucans for the treatment of civilization and viral diseases, with particular emphasis on COVID-19.

scholarly journals Clinical Development of Biological Response Modifiers

1994 ◽  
Vol 5 (suppl a) ◽  
pp. 5A-8A
Author(s):  
Jay P Siegel
Keyword(s):  
Adverse Reactions ◽  
Biological Response ◽  
Clinical Trial Design ◽  
The United States ◽  
Biological Response Modifier ◽  
Clinical Development ◽  
Response Modifier ◽  
United States Food ◽  
Study Population ◽  
States Food

OBJECTIVE: To present perspectives on selected issues that frequently arise during the clinical development of biological response modifier (BRM) therapies.DATA SOURCES: The perspectives and opinions presented herein were developed over several years of reviewing and consulting on the clinical development of BRM therapies at the United States Food and Drug Administration.CONCLUSIONS: BRM therapies encompass a broad spectrum of products used to treat a wide variety of diseases. Due to this diversity. most principles of clinical trial design and conduct applicable to the majority of BRMS are those that are applicable to all therapies. Nevertheless, the clinical development of BRM therapies often raises specific issues and problems in the areas of selecting animal models, defining the study population, adverse reactions, dosing and defining end-points. Over 10 years’ experience in testing biotechnology derived BRMS in clinical trials has created a database from which we can draw valuable generalizations for guidance in future studies.

Inositol-C2-PAF acts as a biological response modifier and antagonizes cancer-relevant processes in mammary carcinoma cells

2018 ◽  
Vol 41 (5) ◽  
pp. 505-516 ◽  
Author(s):  
Carsten Pelz ◽  
Sonja Häckel ◽  
Geo Semini ◽  
Sandra Schrötter ◽  
Willem Bintig ◽  
...  
Keyword(s):  
Mammary Carcinoma ◽  
Biological Response ◽  
Biological Response Modifier ◽  
Carcinoma Cells ◽  
Response Modifier ◽  
Mammary Carcinoma Cells

Development of a water-soluble, sulfated (1 → 3)-β-d-glucan biological response modifier derived from Saccharomyces cerevisiae

1992 ◽  
Vol 235 ◽  
pp. 247-257 ◽  
Author(s):  
David L. Williams ◽  
Henry A. Pretus ◽  
Rose B. McNamee ◽  
Ernest L. Jones ◽  
Harry E. Ensley ◽  
...  
Keyword(s):  
Saccharomyces Cerevisiae ◽  
Biological Response ◽  
Biological Response Modifier ◽  
Water Soluble ◽  
Response Modifier

Antitumor Effect of a Biological Response Modifier, PSK, on C57BL/6 Mice with Syngeneic Melanoma B16 and Its Mode of Action

Oncology ◽  
1994 ◽  
Vol 51 (4) ◽  
pp. 303-308 ◽  
Author(s):  
Kenichi Matsunaga ◽  
Mika Aota ◽  
Yuko Nyunoya ◽  
Mitsunori Hakozaki ◽  
Yoshiaki Ishikawa ◽  
...  
Keyword(s):  
Mode Of Action ◽  
Antitumor Effect ◽  
Biological Response ◽  
Biological Response Modifier ◽  
Response Modifier ◽  
Melanoma B16
Sign in / Sign up

Export Citation Format

Share Document